This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2009 Apr 1;27(10):1540-2.

doi: 10.1200/JCO.2008.19.8457. Epub 2009 Mar 2.

Maintenance or eradication of residual disease in indolent lymphoma: where do we stand?

Anton Hagenbeek

PMID: 19255319
DOI: 10.1200/JCO.2008.19.8457

Editorial

Maintenance or eradication of residual disease in indolent lymphoma: where do we stand?

Anton Hagenbeek. J Clin Oncol. 2009.

. 2009 Apr 1;27(10):1540-2.

doi: 10.1200/JCO.2008.19.8457. Epub 2009 Mar 2.

Author

Anton Hagenbeek

PMID: 19255319
DOI: 10.1200/JCO.2008.19.8457

No abstract available

PubMed Disclaimer

Comment on

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Hochster H, et al. J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255334 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information